Prestige Consumer Healthcare (PBH) Q4 2025 earnings summary

Executive summary

• Achieved record fiscal 2025 revenue of $1,138 billion, up 1.1% year-over-year, driven by international growth, GI category strength, and a diversified brand portfolio.

• Adjusted diluted EPS rose 7.4% to $4.52, aligning with long-term growth objectives.

• E-commerce channel delivered double-digit growth, now representing a high-teens percentage of total sales, with accelerated Q4 performance.

• Free cash flow for fiscal 2025 was $243.3 million, supporting share repurchases and leverage reduction to 2.4x.

• Innovation and marketing agility enabled outperformance in key categories despite supply chain challenges.

Financial highlights

• Q4 revenue was $296.5 million, up 7.9% organically year-over-year, with record adjusted EBITDA and EPS.

• Adjusted diluted EPS for Q4 was $1.32, up from $1.02 in the prior year.

• Fiscal 2025 gross margin was 55.8%, with Q4 gross margin reaching approximately 57%.

• Adjusted EBITDA for fiscal 2025 was $374.5 million (32.9% margin), nearly flat year-over-year.

• Net cash from operating activities for fiscal 2025 was $251.5 million.

Outlook and guidance

• Fiscal 2026 revenue guidance is $1.140–$1.155 billion, with 1%-2% organic growth and a 1% FX headwind.

• Fiscal 2026 adjusted EPS expected at $4.70–$4.82, representing 4%-7% growth.

• Gross margin forecasted at 56.5% for fiscal 2026, despite $15 million in anticipated tariff costs.

• Free cash flow projected at $245 million or more for fiscal 2026.

• Management anticipates a $15 million headwind from inflationary tariffs but plans to mitigate through supply chain agility.